Biotome Pty Ltd

What Biotome Pty Ltd does

Biotome Pty Ltd is an Australian precision immunology company developing peptide-based diagnostic tests and laboratory services for disease risk assessment. Founded in 2017 in Perth, Western Australia by immunologists Dr. Alma Fulurija and Dr. Samuel Lundin, the company is headquartered within the Harry Perkins Institute of Medical Research in Nedlands, with Dr. Lundin serving as CEO and Dr. Barry Marshall (Nobel Laureate, 2005) as co-founder and advisor.

The company's core technology is a proprietary peptide-based precision immunology platform underpinned by two enabling technologies: Peptide Augmentation Technology, which achieves a 10-fold signal improvement over conventional peptide ELISAs without traditional carrier proteins or conjugation chemistry; and Peplock, a surface-binding peptide platform for stable biomolecule immobilisation on solid surfaces (PCT international application filed). The platform supports both ELISA and lateral flow assay formats, with demonstrated lateral flow sensitivity of 0.3 nanograms per millilitre. Two lead diagnostic products are in development: Helitope, a peptide-based blood test validated across 1,200+ patient samples that distinguishes oncogenic CagA-positive H. pylori infections from benign strains for gastric cancer risk stratification (>95% specificity); and PreACT, a first-trimester preeclampsia risk assessment test using antibody signatures for early identification of at-risk pregnancies. Additional products include the Covitope SARS-CoV-2 serology test and an epitope mapping service capable of screening up to 100,000 peptides with AI-guided epitope prediction.

Biotome operates a multi-stream B2B revenue model combining future research-use-only diagnostic kit sales, technology licensing of patented peptide markers and platform IP, and fee-for-service laboratory work (epitope mapping and assay development). Pricing is quote-based and not publicly disclosed. Distribution channels include direct enterprise sales to healthcare systems, clinical laboratories, and research institutions; OEM manufacturing partnership with Biosensis Pty Ltd (first prototype run completed June 2025); and technology licensing to diagnostic manufacturers. The company pursues an enterprise field sales motion supplemented by conference presence (BIO 2025) and digital marketing. Target customer segments span healthcare systems and government health departments (primary), maternal health providers (primary), research institutions and biotech companies (secondary), and diagnostic manufacturers (secondary). The company has raised approximately $5 million in disclosed non-dilutive grant funding across multiple Western Australian government programs and the Leducq Foundation, with first RUO kit production planned for Q4 2025 and no disclosed equity investment rounds to date.

Name

Biotome Pty Ltd

Legal name

Biotome Pty Ltd

Website

https://biotome.com.au

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Biotome Pty Ltd is an Australian precision immunology company developing peptide-based diagnostic tests for gastric cancer risk (Helitope) and preeclampsia risk (PreACT), supported by proprietary Peptide Augmentation and Peplock platform technologies. The company serves healthcare systems, maternal health providers, research institutions, and diagnostic manufacturers via direct sales, licensing, and laboratory services.

Ownership category

akta.pro rank

Product category

Clinical Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Peptide diagnostics
• Precision immunology
• Immunoassay development
• Epitope mapping services
• Gastric cancer diagnostics

Headquarters

HQ city

Perth

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Kit Sales: Sale of research-use-only (RUO) ELISA kits and future clinical diagnostic products. First RUO kit production planned Q4 2025 for Helitope gastric cancer risk assay.
2. Technology Licensing: Licensing of patented peptide markers and platform technology to diagnostic companies and strategic partners worldwide. Multiple commercialisation pathways including custom peptide manufacturing, full-service diagnostic development, and direct technology licensing.
3. Laboratory Services: Fee-for-service epitope mapping and assay development for research partners. Services include high-density peptide microarrays, bioinformatics analysis, and custom assay development.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Biotome develops and sells peptide-based precision immunology diagnostic kits (Helitope for gastric cancer risk and PreACT for preeclampsia risk) and provides fee-for-service laboratory offerings including high-density peptide microarray epitope mapping and custom peptide-ELISA assay development. The company also licenses its patented peptide biomarker portfolio and proprietary platform technologies (Peptide Augmentation Technology and Peplock) to diagnostic manufacturers and strategic partners globally.

Product overview

Biotome is a precision immunology company offering a peptide-based diagnostic platform with two lead products: Helitope (gastric cancer risk test) and PreACT (preeclampsia risk test). The platform is powered by proprietary technologies including Peplock (biomolecule anchoring) and Peptide Augmentation Technology (signal enhancement). Services include epitope mapping, assay development, and IP licensing. The company provides research-use-only ELISA kits and is transitioning to manufactured diagnostic products.

Differentiator

Problem solved

Functional benefit

Brands

• Helitope: Peptide-based blood test for gastric cancer risk that identifies CagA-positive Helicobacter pylori infections with elevated cancer risk.
• PreACT
• Peplock
• Covitope

Products and services

• Helitope Gastric Cancer Risk Test Peptide-based blood test that identifies individuals carrying CagA-positive Helicobacter pylori infections by detecting antibodies specific to oncogenic CagA epitopes. Validated across more than 1,200 patient samples with >95% specificity for distinguishing oncogenic from benign H. pylori strains, enabling targeted gastric cancer prevention and risk-stratified treatment decisions.
• PreACT Preeclampsia Risk Test First-trimester preeclampsia risk assessment test that detects specific antibody signatures in maternal blood weeks before protein biomarkers appear, identifying women at elevated risk when aspirin intervention is most effective. Designed for compatibility with standard laboratory equipment and use in resource-limited settings where the majority of preeclampsia deaths occur.
• Epitope Mapping and Antibody Characterisation Service High-density peptide microarray-based service supporting up to 100,000 peptides for mapping antibody responses and identifying immunogenic regions on proteins and pathogens. Includes whole-proteome or protein-specific design, linear and conformational epitope analysis, isotyping and subclassing, specificity and cross-reactivity profiling, and permutation/alanine scans. Delivered with AI-guided epitope prediction and bioinformatics analysis.
• Peptide Optimisation and Assay Development Service Full-service peptide-ELISA development from biomarker discovery through to manufacturing-ready prototypes. Covers peptide optimisation and synthesis, matrix screening across serum, plasma, dried blood spots and saliva, multiplex panel development, and ELISA format conversion for both lab-based and point-of-care platforms. Includes regulatory pathway guidance.
• Peplock Biomolecule Anchoring Platform (Licensed) Surface-binding peptide platform for stable biomolecule immobilisation on solid surfaces, licensed to partners for use in immunoassays, biosensors, and antimicrobial surfaces. Uses compact peptide anchor elements to immobilise peptides, proteins, antibodies, enzymes, and other functional biomolecules while preserving their function.
• Peptide Augmentation Technology (Licensed) Patent-pending peptide modification technology that directly modifies peptides to dramatically increase ELISA sensitivity without traditional conjugation chemistry, carrier proteins, or external coupling agents. Delivers 10-fold signal enhancement over standard peptide ELISA with extremely low non-specific binding for clinical-grade specificity. Licensed to diagnostic companies and strategic partners worldwide.

Quantifiable outcome

• 10-fold improvement in signal-to-noise ratio compared to conventional peptide ELISAs
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and strategic.

• Biosensis Pty LtdcoreTechnology or Integration · 30 May 2025Manufacturing partnership for production of prototype diagnostic test kits. Biosensis provides manufacturing expertise and quality systems for scalable production of peptide-ELISA kits including the Helitope gastric cancer risk assay. First prototype production run completed June 2025.
• Leducq Foundation - Acute Rheumatic Fever Diagnosis Collaborative Network (ARC Network)strategicStrategic or Co-development Partner · 14 September 2022International consortium focused on discovering biomarkers for acute rheumatic fever diagnosis. Led by Dr. Andrea Beaton (Cincinnati Children's Hospital) with research groups from 12 countries across all continents. Biotome contributes expertise in antibody response characterisation.
• MTP ConnectcoreStrategic or Co-development PartnerStrategic guidance and industry connections through Australian MedTech and Pharma industry growth centre. Part of Western Australia's biotechnology ecosystem supporting company growth and commercialisation.
• Life Sciences WAcoreStrategic or Co-development PartnerStrategic guidance and industry connections within Western Australian life sciences sector. Supports company positioning and partnership development within the regional biotech ecosystem.
• Harry Perkins Institute of Medical ResearchcoreStrategic or Co-development PartnerResearch infrastructure partner housing Biotome's laboratory facilities. Provides access to world-class research facilities and clinical networks supporting diagnostic development.
• The Marshall Centre at UWAstrategicStrategic or Co-development PartnerClinical expertise and patient cohorts for gastric cancer research. Named after Nobel Laureate Dr. Barry Marshall, co-founder, providing clinical research collaboration and access to study populations.
• Beacon ScientificstrategicStrategic or Co-development PartnerCollaboration on feasibility study for peptide-based lateral flow device targeting CagA-positive H. pylori. Beacon provided expertise in testing both competitive and sandwich assay formats.
• Telethon Kids InstitutestrategicStrategic or Co-development PartnerPerth-based research partner within ARC Network consortium. Dr. Timothy Barnett and colleagues contribute clinical expertise and patient cohorts for acute rheumatic fever biomarker research.
• The Institute for Respiratory HealthstrategicStrategic or Co-development PartnerResearch collaboration on idiopathic pulmonary fibrosis (IPF). Characterising autoantibody responses to identify IPF patients who may benefit from immunosuppression. Validating autoantigen targets using peptide microarrays.
• Kids Research Institute AustraliastrategicStrategic or Co-development PartnerResearch collaboration on acute rheumatic fever and rheumatic heart disease. Mapping antibody responses to entire Strep A proteome to distinguish protective immunity from harmful cross-reactivity. Includes prototype serology diagnostic development.
• The Perron InstitutestrategicStrategic or Co-development PartnerResearch collaboration on multiple sclerosis. Mapping EBV-specific antibody signatures in clinically isolated syndrome (CIS). Complements Perron's T cell studies with B cell response characterisation.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

Emerging players

• AbCellera Biologics: Clinical-stage biotech developing antibody discovery platform using single-cell screening and AI-guided antibody engineering. Comparable to Biotome's protein engineering and antibody discovery capabilities, though AbCellera operates at greater scale and broader therapeutic focus.

Broad incumbents

• Revvity (formerly PerkinElmer Life Sciences): Major life sciences and diagnostics company with significant prenatal screening and maternal health diagnostic offerings. Comparable to Biotome's PreACT preeclampsia diagnostic ambitions and broader clinical diagnostic product portfolio.
• DiaSorin: Italian diagnostics company with H. pylori testing products and broad specialty immunoassay portfolio. Comparable to Biotome's Helitope gastric cancer risk diagnostic from a clinical positioning standpoint, particularly in addressing H. pylori-related disease stratification.
• Bio-Rad Laboratories: Major life science research and clinical diagnostics company offering ELISA kits, immunoassay reagents, and protein/peptide research tools. Directly comparable to Biotome's research-use ELISA kit product line and assay development services, though operating at vastly greater scale across many diagnostic categories.
• GenScript: Global biotech providing peptide synthesis, antibody services, protein engineering, and cell therapy services. Comparable to Biotome across peptide manufacturing, antibody discovery, and assay development service offerings, with broader service portfolio and far larger scale.

Direct peers

• Quanterix: Developer of ultra-sensitive single-molecule array (Simoa) immunoassay technology for biomarker detection in research and clinical diagnostics. Comparable to Biotome in pursuing step-change improvements in immunoassay sensitivity and developing diagnostic applications in areas like neurology and oncology.
• Gyros Protein Technologies: Developer of peptide synthesis instrumentation and immunoassay platforms for biotherapeutic development and biomarker quantification. Comparable to Biotome across peptide-based diagnostic development and bioanalytical services.
• RayBiotech: Developer of antibody arrays, ELISA kits, and proteomics services for biomarker discovery and validation. Comparable to Biotome's epitope mapping service and custom assay development offerings, with similar customer base in academic and translational research.
• Carterra: Provider of high-throughput antibody characterization and epitope mapping instruments using surface plasmon resonance and microarray technology. Directly comparable to Biotome's high-density peptide microarray epitope mapping service and antibody profiling capabilities.
• Meso Scale Diagnostics: Developer of ultra-sensitive electrochemiluminescence immunoassay platforms for biomarker detection and clinical diagnostics. Comparable in pursuing high-sensitivity multiplexed immunoassays for clinical and research applications, and serves as a benchmark for what Biotome's peptide-augmentation technology aims to disrupt in assay sensitivity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biotome-pty-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biotome Pty Ltd